Japanese company profile · 4887
SAWAI GROUP HOLDINGS Co., Ltd.
In its FY2024 public filing, SAWAI GROUP HOLDINGS Co., Ltd. reports Manufacturing and Sales of Pharmaceuticals and Related Products. The page shows business-level revenue and profit where the source disclosures support comparison.
Original Japanese company name: サワイグループホールディングス株式会社
English company name recorded in Japan's EDINET filer data. English company name source
Reported company-wide figures
What does this company do?
What does this company do?
SAWAI GROUP HOLDINGS Co., Ltd.'s largest reported business by revenue in FY2024 was Manufacturing and Sales of Pharmaceuticals and Related Products.
The business with the highest reported segment profit in FY2024 was Manufacturing and Sales of Pharmaceuticals and Related Products.
FY2024 · fiscal year ended March 2025 View original filing ↗ The source document may be in Japanese.
Business structure
How does it make money?
| Business | Segment revenue | Revenue share | Segment profit (loss) |
|---|---|---|---|
| Manufacturing and Sales of Pharmaceuticals and Related Products | ¥189.02B ↗ | 100.0% | ¥4.05B ↗ |
All values are in Japanese yen (JPY). No currency conversion is applied. FY2024 · fiscal year ended March 2025. Revenue and profit are shown only where the filing and data support a comparison.
Original Japanese label
- Manufacturing and Sales of Pharmaceuticals and Related Products
- 医薬品等の製造及び販売
- Japan
- 日本
- United States
- 米国
- Segment revenue
- セグメント収益
- Segment profit (loss)
- セグメント利益（損失）
Original Japanese label
- Manufacturing and Sales of Pharmaceuticals and Related Products
- 医薬品等の製造及び販売
- Japan
- 日本
- United States
- 米国
- Segment revenue
- セグメント収益
- Segment profit (loss)
- セグメント利益（損失）
Reported Segment revenue by business over time
Reported Segment revenue by business over time
| Fiscal year | FY2021 | FY2022 | FY2024 |
|---|---|---|---|
| Manufacturing and Sales of Pharmaceuticals and Related Products | — | — | ¥189.02B |
| Japan | ¥163.84B | ¥163.7B | — |
| United States | ¥29.98B | ¥36.64B | — |
All amounts are in Japanese yen (JPY). Each figure links to the original Japanese filing. Blank cells indicate no comparable figure was disclosed. Business figures may not add up to consolidated figures.
What is growing?
What is growing?
No comparable reported revenue growth is available.
What has changed?
What has changed?
Not disclosed or not safely comparable in the available filings.
Source
Public filing
FY2024 · fiscal year ended March 2025
The source document may be in Japanese.
Filing ID: S100W39J
View original filing ↗Ask about this company
Ask about this company
The source document may be in Japanese.